Keratoconjunctivitis
Methodology & AI Transparency ⓘ
Keratoconjunctivitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as H16.209, Keratoconjunctivitis falls under Eyes & Vision management, where AREDS2 macular nutrition [Keratoconjunctivitis H16.209] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Keratoconjunctivitis uses ICD-10 H16.209 across Eyes & Vision specialty care.
- 3 Typical cash cost range: Differential triage of Keratoconjunctivitis (H16.209) utilizes AREDS2 macular nutrition [Keratoconjunctivitis H16.209].
- 4 Top reported side effects / signs: Follow-up benchmark in Keratoconjunctivitis: maintaining Intraocular Pressure (IOP) [Keratoconjunctivitis H16.209] within 10 – 21 mmHg (individualized optic target) (H16.209).
Ask our AI Specialists anything about Keratoconjunctivitis
What Is Keratoconjunctivitis?
Designated in federal medical registries as H16.209, Keratoconjunctivitis falls under Eyes & Vision management, where AREDS2 macular nutrition [Keratoconjunctivitis H16.209] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Keratoconjunctivitis (H16.209) features microvascular diabetic/hypertensive retinopathy [Keratoconjunctivitis H16.209]. therapeutic stabilization in eyes & vision is verified against Best-Corrected Visual Acuity in Keratoconjunctivitis (H16.209: & OCT).
Common Symptoms & Clinical Signs
- • Presentation of Keratoconjunctivitis (H16.209): acute eye redness, in Keratoconjunctivitis (H16.209: discharge, photophobia, or)
- • Secondary Keratoconjunctivitis clinical sign: gradual blurring, glare/halos in Keratoconjunctivitis (H16.209: around nighttime headlights,)
- • Symptom flares in Keratoconjunctivitis correlating with Intraocular Pressure (IOP) [Keratoconjunctivitis H16.209] deviation outside 10 – 21 mmHg (individualized optic target) (H16.209)
- • Functional eyes & vision impact requiring AREDS2 macular nutrition [Keratoconjunctivitis H16.209] evaluation (H16.209)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Keratoconjunctivitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H16.209 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Keratoconjunctivitis H16.209] | 10 – 21 mmHg (individualized optic target) (H16.209) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Keratoconjunctivitis (H16.209: & OCT) | Intact retinal nerve fiber & macula (H16.209) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Keratoconjunctivitis (H16.209: Blood Pressure) | Microvascular retinal protection (H16.209) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Keratoconjunctivitis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Cyclosporine Verkazia, Sandimmune • RxCUI 2590608 | Calcineurin Inhibitor Immunosuppressant | 75% | $2.8312 | $ 31.73 /mo |
| Verkazia (Cyclosporine) Verkazia • RxCUI 2590613 | Calcineurin Inhibitor Immunosuppressant | 77% | $1.8496 | $ 141.67 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Keratoconjunctivitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of a new water-free skin-applied cyclosporine 0.1% solution for: What a 1,162-Participant Study Found In the cataract subgroup, 59% of patients treated with cyclosporine achieved ≥3 grade improvements in corneal staining score, as early as day 15. Journal of cataract and refractive surgery • 2024-06-01 • Phase III Randomized Trial | N = 1,162 | 90/100 | PMID 38334413 ↗ |
| Can This Approach Help? Inside the Latest Research on Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Sham-treated eyes with ORT at baseline had less loss of BCVA over 24 months than eyes without ORT. Ophthalmic surgery, lasers & imaging retina • 2025-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39918755 ↗ |
| Can This Approach Help? Inside the Latest Research on NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of All groups showed improvement in subjective VKC symptoms at day 28, without a statistically significant difference between 0.05% or 0.1% CsA-CE vs vehicle. Clinical therapeutics • 2023-12-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37872059 ↗ |
| Can This Approach Help? Inside the Latest Research on Expanding insights from the VISTA phase III trial: longitudinal comparative No significant differences in treatment response were observed across racial/ethnic groups. Scientific reports • 2025-12-05 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41350590 ↗ |
| Can This Approach Help? Inside the Latest Research on Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Clinically and statistically significant improvements in ICSS, tear production, and symptoms were observed in participants administered CyclAGel 0.05% QD for moderate-to-severe DED. Drug design, development and therapy • 2022-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36164414 ↗ |
Keratoconjunctivitis Patient Community & “People Like Me” Threads
Filter Keratoconjunctivitis community threads and patient logs by age, biological sex, dosage, and treatment duration.